Exploration of the feasibility of clinical application of phage treatment for multidrug-resistant Serratia marcescens-induced pulmonary infection
Serratia marcescens (S. marcescens) commonly induces refractory infection due to its multidrug-resistant nature. To date, there have been no reports on the application of phage treatment for S. marcescens infection. This study was conducted to explore the feasibility of phage application in treating...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2025.2451048 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841527050586816512 |
|---|---|
| author | Xiangke Duan Wenfeng Liu Yanyu Xiao Man Rao Liyin Ji Xiaofu Wan Shuhong Han Zixun Lin Haichen Liu Peifen Chen Kun Qiao Mingbin Zheng Jiayin Shen Yang Zhou Tetsuya Asakawa Minfeng Xiao Hongzhou Lu |
| author_facet | Xiangke Duan Wenfeng Liu Yanyu Xiao Man Rao Liyin Ji Xiaofu Wan Shuhong Han Zixun Lin Haichen Liu Peifen Chen Kun Qiao Mingbin Zheng Jiayin Shen Yang Zhou Tetsuya Asakawa Minfeng Xiao Hongzhou Lu |
| author_sort | Xiangke Duan |
| collection | DOAJ |
| description | Serratia marcescens (S. marcescens) commonly induces refractory infection due to its multidrug-resistant nature. To date, there have been no reports on the application of phage treatment for S. marcescens infection. This study was conducted to explore the feasibility of phage application in treating refractory S. marcescens infection by collaborating with a 59-year-old male patient with a pulmonary infection of multidrug-resistant S. marcescens. Our experiments included three domains: i) selection of the appropriate phage, ii) verification of the efficacy and safety of the selected phage, iii) confirmation of phage-bacteria interactions. Our results showed that phage Spe5P4 is appropriate for S. marcescens infection. Treatment with phage Spe5P4 showed good efficacy, manifested as amelioration of symptoms, hydrothorax examinations, and chest computed tomography findings. Phage treatment did not worsen hepatic and renal function, immunity-related indices, or indices of routine blood examination. It did not induce or deteriorate drug resistance of the involved antibiotics. Importantly, no adverse events were reported during the treatment or follow-up periods. Thus, phage treatment showed satisfactory safety. Finally, we found that phage treatment did not increase the bacterial load, cytotoxicity, virulence, or phage resistance of S. marcescens, indicating satisfactory phage-bacteria interactions between Spe5P4 and S. marcescens, which are useful for the future application of phage Spe5P4 against S. marcescens. This work provides evidence and a working basis for further application of phage Spe5P4 in treating refractory S. marcescens infections. We also provided a methodological basis for investigating clinical application of phage treatment against multidrug-resistant bacterial infections in the future. |
| format | Article |
| id | doaj-art-b988b068a29247a7b8249bcfcaf8cd36 |
| institution | Kabale University |
| issn | 2222-1751 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj-art-b988b068a29247a7b8249bcfcaf8cd362025-01-16T07:28:39ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512025-12-0114110.1080/22221751.2025.2451048Exploration of the feasibility of clinical application of phage treatment for multidrug-resistant Serratia marcescens-induced pulmonary infectionXiangke Duan0Wenfeng Liu1Yanyu Xiao2Man Rao3Liyin Ji4Xiaofu Wan5Shuhong Han6Zixun Lin7Haichen Liu8Peifen Chen9Kun Qiao10Mingbin Zheng11Jiayin Shen12Yang Zhou13Tetsuya Asakawa14Minfeng Xiao15Hongzhou Lu16Department of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen, People’s Republic of ChinaBGI Research, Shenzhen, People’s Republic of ChinaDepartment of Clinical Laboratory, National Clinical Research Center for Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen, People’s Republic of ChinaDepartment of Infection and Immunology, National Clinical Research Center for Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen, People’s Republic of ChinaDepartment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen, People’s Republic of ChinaDepartment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen, People’s Republic of ChinaDepartment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen, People’s Republic of ChinaDepartment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen, People’s Republic of ChinaBGI Research, Shenzhen, People’s Republic of ChinaDepartment of Respiratory Medicine, National Clinical Research Center for Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen, People’s Republic of ChinaDepartment of Thoracic Surgery, National Clinical Research Center for Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen, People’s Republic of ChinaDepartment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen, People’s Republic of ChinaDepartment of Science and Education, National Clinical Research Center for Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen, People’s Republic of ChinaDepartment of Infection and Immunology, National Clinical Research Center for Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen, People’s Republic of ChinaInstitute of Neurology, National Clinical Research Center for Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen, People’s Republic of ChinaBGI Research, Shenzhen, People’s Republic of ChinaDepartment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen, People’s Republic of ChinaSerratia marcescens (S. marcescens) commonly induces refractory infection due to its multidrug-resistant nature. To date, there have been no reports on the application of phage treatment for S. marcescens infection. This study was conducted to explore the feasibility of phage application in treating refractory S. marcescens infection by collaborating with a 59-year-old male patient with a pulmonary infection of multidrug-resistant S. marcescens. Our experiments included three domains: i) selection of the appropriate phage, ii) verification of the efficacy and safety of the selected phage, iii) confirmation of phage-bacteria interactions. Our results showed that phage Spe5P4 is appropriate for S. marcescens infection. Treatment with phage Spe5P4 showed good efficacy, manifested as amelioration of symptoms, hydrothorax examinations, and chest computed tomography findings. Phage treatment did not worsen hepatic and renal function, immunity-related indices, or indices of routine blood examination. It did not induce or deteriorate drug resistance of the involved antibiotics. Importantly, no adverse events were reported during the treatment or follow-up periods. Thus, phage treatment showed satisfactory safety. Finally, we found that phage treatment did not increase the bacterial load, cytotoxicity, virulence, or phage resistance of S. marcescens, indicating satisfactory phage-bacteria interactions between Spe5P4 and S. marcescens, which are useful for the future application of phage Spe5P4 against S. marcescens. This work provides evidence and a working basis for further application of phage Spe5P4 in treating refractory S. marcescens infections. We also provided a methodological basis for investigating clinical application of phage treatment against multidrug-resistant bacterial infections in the future.https://www.tandfonline.com/doi/10.1080/22221751.2025.2451048Phage treatmentphage Spe5P4Serratia marcescens (S. marcescens)multidrug-resistanceefficacy and safety |
| spellingShingle | Xiangke Duan Wenfeng Liu Yanyu Xiao Man Rao Liyin Ji Xiaofu Wan Shuhong Han Zixun Lin Haichen Liu Peifen Chen Kun Qiao Mingbin Zheng Jiayin Shen Yang Zhou Tetsuya Asakawa Minfeng Xiao Hongzhou Lu Exploration of the feasibility of clinical application of phage treatment for multidrug-resistant Serratia marcescens-induced pulmonary infection Emerging Microbes and Infections Phage treatment phage Spe5P4 Serratia marcescens (S. marcescens) multidrug-resistance efficacy and safety |
| title | Exploration of the feasibility of clinical application of phage treatment for multidrug-resistant Serratia marcescens-induced pulmonary infection |
| title_full | Exploration of the feasibility of clinical application of phage treatment for multidrug-resistant Serratia marcescens-induced pulmonary infection |
| title_fullStr | Exploration of the feasibility of clinical application of phage treatment for multidrug-resistant Serratia marcescens-induced pulmonary infection |
| title_full_unstemmed | Exploration of the feasibility of clinical application of phage treatment for multidrug-resistant Serratia marcescens-induced pulmonary infection |
| title_short | Exploration of the feasibility of clinical application of phage treatment for multidrug-resistant Serratia marcescens-induced pulmonary infection |
| title_sort | exploration of the feasibility of clinical application of phage treatment for multidrug resistant serratia marcescens induced pulmonary infection |
| topic | Phage treatment phage Spe5P4 Serratia marcescens (S. marcescens) multidrug-resistance efficacy and safety |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2025.2451048 |
| work_keys_str_mv | AT xiangkeduan explorationofthefeasibilityofclinicalapplicationofphagetreatmentformultidrugresistantserratiamarcescensinducedpulmonaryinfection AT wenfengliu explorationofthefeasibilityofclinicalapplicationofphagetreatmentformultidrugresistantserratiamarcescensinducedpulmonaryinfection AT yanyuxiao explorationofthefeasibilityofclinicalapplicationofphagetreatmentformultidrugresistantserratiamarcescensinducedpulmonaryinfection AT manrao explorationofthefeasibilityofclinicalapplicationofphagetreatmentformultidrugresistantserratiamarcescensinducedpulmonaryinfection AT liyinji explorationofthefeasibilityofclinicalapplicationofphagetreatmentformultidrugresistantserratiamarcescensinducedpulmonaryinfection AT xiaofuwan explorationofthefeasibilityofclinicalapplicationofphagetreatmentformultidrugresistantserratiamarcescensinducedpulmonaryinfection AT shuhonghan explorationofthefeasibilityofclinicalapplicationofphagetreatmentformultidrugresistantserratiamarcescensinducedpulmonaryinfection AT zixunlin explorationofthefeasibilityofclinicalapplicationofphagetreatmentformultidrugresistantserratiamarcescensinducedpulmonaryinfection AT haichenliu explorationofthefeasibilityofclinicalapplicationofphagetreatmentformultidrugresistantserratiamarcescensinducedpulmonaryinfection AT peifenchen explorationofthefeasibilityofclinicalapplicationofphagetreatmentformultidrugresistantserratiamarcescensinducedpulmonaryinfection AT kunqiao explorationofthefeasibilityofclinicalapplicationofphagetreatmentformultidrugresistantserratiamarcescensinducedpulmonaryinfection AT mingbinzheng explorationofthefeasibilityofclinicalapplicationofphagetreatmentformultidrugresistantserratiamarcescensinducedpulmonaryinfection AT jiayinshen explorationofthefeasibilityofclinicalapplicationofphagetreatmentformultidrugresistantserratiamarcescensinducedpulmonaryinfection AT yangzhou explorationofthefeasibilityofclinicalapplicationofphagetreatmentformultidrugresistantserratiamarcescensinducedpulmonaryinfection AT tetsuyaasakawa explorationofthefeasibilityofclinicalapplicationofphagetreatmentformultidrugresistantserratiamarcescensinducedpulmonaryinfection AT minfengxiao explorationofthefeasibilityofclinicalapplicationofphagetreatmentformultidrugresistantserratiamarcescensinducedpulmonaryinfection AT hongzhoulu explorationofthefeasibilityofclinicalapplicationofphagetreatmentformultidrugresistantserratiamarcescensinducedpulmonaryinfection |